A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) (NCT06885034)
A Phase1 b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Los Alamitos, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (85 Sites)
Showing the first 25 of 85 sites.
- GSK Investigational Site — Los Alamitos, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Santa Monica, California
- GSK Investigational Site — Whittier, California
- GSK Investigational Site — Aurora, Colorado
- GSK Investigational Site — New York, New York
- GSK Investigational Site — New York, New York
- GSK Investigational Site — Durham, North Carolina
- GSK Investigational Site — Houston, Texas
- GSK Investigational Site — San Antonio, Texas
- GSK Investigational Site — Wenatchee, Washington
- GSK Investigational Site — Madison, Wisconsin
- GSK Investigational Site — Heidelberg, Victoria
- GSK Investigational Site — Melbourne, Victoria
- GSK Investigational Site — Bonheiden,
- GSK Investigational Site — Brussels,
- GSK Investigational Site — Leuven,
- GSK Investigational Site — Roeselare,
- GSK Investigational Site — Porto Alegre,
- GSK Investigational Site — São Paulo,
- GSK Investigational Site — Teresina,
- GSK Investigational Site — Calgary, Alberta
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Montreal, Quebec
- GSK Investigational Site — Sherbrooke, Quebec
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastrointestinal Neoplasms
- Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei — Houston, Texas
- Monopolar Current Cutting Knife vs Bipolar RFA Knife — Houston, Texas
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors — Miami, Florida
- Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer — Duarte, California
- Feasibility and Prospective Study of a Dynamic Traction Device for Use During ESD — Houston, Texas
- The Canopy Cancer Collective Clinical Registry Protocol — San Diego, California
Explore by condition: All Gastrointestinal Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.